Smain Sadok, MD
Family Medicine · Chicago, ILNPI 1891916383
Payments from drug & device makers
Across 400 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$1K
- Pfizer$586
- AbbVie$482
- Johnson & Johnson$395
- Bayer$288
- plus $3K from 28 others
What the payments were for
- Food & beverage$8,095100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 104 | $1,945 |
| Lilly USA, LLC | 61 | $1,281 |
| Pfizer | 27 | $586 |
| AbbVie(2 entities) | 23 | $482 |
| Johnson & Johnson | 19 | $395 |
| Bayer | 11 | $288 |
| Sunovion Pharmaceuticals Inc. | 15 | $274 |
| Novo Nordisk | 13 | $267 |
| E.r. Squibb & Sons, L.L.C. | 13 | $267 |
| Novartis | 12 | $249 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $244 |
| Merck | 13 | $236 |
| Otsuka America Pharmaceutical, Inc. | 10 | $220 |
| Preventric Diagnostics, Inc. | 2 | $197 |
| Sanofi-aventis U.S. LLC | 12 | $187 |
| GSK | 10 | $169 |
| Xeris Pharmaceuticals, Inc. | 7 | $145 |
| Exact Sciences | 5 | $118 |
| Boehringer Ingelheim | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 4 | $77 |
| Amarin Pharma, Inc. | 4 | $71 |
| Ardelyx, Inc. | 2 | $58 |
| Sumitomo Pharma America, Inc. | 2 | $49 |
| Amgen | 2 | $31 |
| Gilead | 1 | $29 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Biogen | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Medtronic | 1 | $19 |
| Echosens North America, Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Abbott | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
How this compares
$8,112 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 695 | $181,020 |
| JardianceEmpagliflozin | 191 | $98,204 |
| XareltoRivaroxaban | 178 | $45,908 |
| EntrestoSacubitril/Valsartan | 89 | $40,182 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $37,506 |
| FarxigaDapagliflozin Propanediol | 26 | $32,203 |
| LinzessLinaclotide | 43 | $31,897 |
| JanuviaSitagliptin Phosphate | 105 | $28,587 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $19,821 |
| MounjaroTirzepatide | 17 | $17,389 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $16,123 |
| TradjentaLinagliptin | 17 | $14,402 |
| Atorvastatin Calcium | 1,807 | $12,563 |
| GlyxambiEmpagliflozin/Linagliptin | 14 | $10,768 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 32 | $10,689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $586 | $191,709727 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Spiriva Respimat | $83 | $129,461233 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,945 | $52,02446 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $169 | $49,81078 claims |
| Johnson & JohnsonXarelto | $395 | $45,908178 claims |
| NovartisEntresto | $249 | $40,18289 claims |
| AbbVieLinzess | $482 | $31,89743 claims |
| MerckJanuvia | $236 | $28,587105 claims |
| Lilly USA, LLCMounjaro | $1,281 | $17,38917 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $187 | $16,12314 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $220 | $4,75013 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $49 | $4,47321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Chicago
- Bradley TorphyChicago$3M
- Frank PhillipsChicago$1.6M
- Ayoade AkereChicago$484K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
- Jacqueline OlivoChicago$165K
- Sameer PanjwaniChicago$136K
- Igor AltmanChicago$64K
- Juan RojasChicago$40K
- Mark SimonChicago$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.